Cholesterol, inflammation shifts tied to disability in progressive MS
Lower HDL, higher levels of some proteins point to more severe disease
Written by |
Researchers studied the link between cholesterol and inflammation markers and progressive forms of MS. (Photo by iStock)
- A study tied progressive multiple sclerosis severity to disrupted cholesterol metabolism and chronic inflammation.
- Severe disability is characterized by lower HDL cholesterol and elevated markers of inflammation.
- Future treatments may focus on multi-pathway biomarker networks, the researchers said.
A study linked abnormalities in cholesterol metabolism and elevated inflammatory markers to more severe disability in people with progressive forms of multiple sclerosis (MS).
“Our results demonstrate marked alterations in metabolic, inflammatory, nutritional, and [brain cell] biomarker networks in Severe [progressive MS], and that disrupted cholesterol metabolism and chronic inflammation are associated with greater disability in Severe [progressive] MS,” researchers wrote.
The study, “Dysregulated Cholesterol Metabolism, Chronic Inflammation, and Disability in Severe Progressive Multiple Sclerosis,” was published in the Annals of Clinical and Translational Neurology.
MS is driven by inflammation in the brain and spinal cord, which causes damage to the myelin sheath, a fatty covering that helps nerve fibers send electrical signals more efficiently. This disrupts neurological signaling, ultimately driving MS symptoms.
In progressive forms of MS — including primary progressive and secondary progressive disease — symptoms gradually worsen over time, regardless of whether patients experience occasional flares. But the rate at which symptoms progress can vary dramatically from person to person, and the reasons for this variation are not well understood.
Study groups patients by disability level
A team of U.S. scientists wondered if differences in inflammation profiles and cholesterol metabolism might contribute to differences in disability progression among people with progressive MS. Cholesterol is a fatty molecule that plays important roles in many biological processes within the body — and in the context of MS, cholesterol is a key component of the myelin sheath.
For their study, the researchers enrolled two groups of progressive MS patients who differed in terms of disability. One group, termed severe progressive MS, consisted of patients whose MS had taken away the ability to walk. Most of these patients needed assistance to get around in a wheelchair. The other group, referred to as control progressive MS, had at least moderate disability, but all were able to walk, even if they needed an aid like a cane to do it.
There were 53 patients in each group, and the two groups were selected so that factors such as age, sex, and disease duration would be similar.
The researchers collected blood samples and measured cholesterol levels as well as several related molecules and various indices of chronic inflammation. They then used statistical analyses to compare the severe and control groups.
Results showed that the severe group had significantly lower levels of high-density lipoprotein cholesterol (HDL), a form of cholesterol that’s commonly referred to as good cholesterol because it can help reduce the risk of certain cardiovascular issues.
The groups also had differences in several apolipoproteins, proteins that help regulate the movement of cholesterol and related fatty molecules in the bloodstream. For example, ApoB and ApoE levels were elevated in the severe group, and ApoA-I, and ApoA-II levels were reduced.
At the same time, the severe group had significantly higher levels of markers associated with chronic inflammation.
The researchers also investigated whether differences in cholesterol metabolism and inflammation were associated with patients’ disability levels. They assessed disability using two measures: the Expanded Disability Status Scale, which evaluates neurological impairment, and the Combinatorial Weight-Adjusted Disability scale, which incorporates additional measures of cognitive and physical function.
Statistical analyses showed that total cholesterol, ApoA-II, and ApoB levels were associated with disability scores on both scales. Levels of low-density lipoprotein (LDL) cholesterol, often referred to as bad cholesterol, were also associated with disability on both measures.
“Disrupted cholesterol metabolism and chronic inflammation are strongly linked to greater disability in Severe [progressive MS],” the researchers concluded.
The researchers noted that the cholesterol-lowering medication simvastatin has been tested in clinical trials, with somewhat disappointing results: Early studies indicated that the therapy may reduce brain atrophy (shrinkage), but a large Phase 3 data found that the treatment was no better than a placebo at preventing disability progression.
But early trials of simvastatin for MS focused on just a few disease biomarkers, mostly reflecting brain cell health, the researchers said. They proposed that their approach, which encompasses many different markers across multiple biological pathways, may be more informative for figuring out how to translate these research findings into better outcomes for patients.
“Our multimodal approach of interrogating validated sentinel biomarkers, spanning diverse physiological pathways, in the context of Severe PMS represents a promising strategy for identifying new treatment approaches,” the team wrote.
Leave a comment
Fill in the required fields to post. Your email address will not be published.